with podocyte-specific overexpression of the VEGF 164 isoform develop a collapsing glomerulopathy that resembles the classic renal lesion seen in HIV-associated nephropathy (HIVAN). 6 Data have also provided evidence that VEGF may act as an autocrine factor for podocytes. 7 The collapsing glomerular lesions that are classically seen in HIVAN are associated with podocyte proliferation and loss of podocyte differentiation markers, including WT1 and synaptopodin. 8, 9 In this study, we sought to determine whether VEGF is upregulated in podocytes from mice with HIVAN and whether blockade of VEGF receptors can ameliorate the podocyte proliferation and de-differentiation induced by HIV.
First, the expression of VEGF and hypoxia-inducible factor (HIF) was studied in vivo. By immunostaining, we found increased staining for both VEGF and its transcriptional regulator HIF-2␣ in kidneys of patients with HIVAN as well as in kidneys from Tg26 mice when compared with controls ( Figure 1 ). We were not able to perform co-localization studies to determine whether the staining was podocyte specific because the markers of differentiation in podocytes are suppressed in Tg26 mice even in the absence of proliferation (Supplemental Figure 1 ). 8 One limitation of our immunostaining is that VEGF staining with available antibodies does not distinguish between the proangiogenic (VEGF 165 ) and antiangiogenic (VEGF 165b ) isoforms. VEGF 165b binds VEGFR2 with the same affinity as VEGF 165 but does not activate or stimulate downstream signaling path-ways, thereby preventing VEGF 165 -mediated cell signaling. 10 VEGF 165b has been shown to be highly expressed in differentiated but not in de-differentiated podocytes. 11 Next, we studied how HIV regulates VEGF expression in cultured podocytes. We found that the VEGF isoforms 164 and 188 were upregulated at the mRNA level in HIV-infected podocytes when compared with control cells, and protein expression of VEGF 164 was increased ( Figure 2 , A and B). Treatment with MG132, a proteasomal inhibitor, augmented levels of VEGF in control podocytes, whereas treatment with MG132 in HIV-infected podocytes did not significantly increase levels of VEGF expression ( Figure 2 , B and D). We determined whether HIF levels are increased in HIVinfected podocytes, because HIF is known to activate transcription of VEGF and MG132 blocks degradation of HIF. Whereas treatment with MG132 slightly increased both HIF-1␣ and HIF-2␣ protein levels, HIV-infected podocytes had markedly increased expression of HIF-2␣ when compared with control podocytes ( Figure 2C ). Expression of HIF-1␣ did not change after HIV infection ( Figure 2C ). Our data suggest that HIV increases VEGF expression through stimulation of HIF-2␣. HIF plays a key role in hypoxic conditions and serves as a transcription factor for genes that mediate adaptive responses to reduced oxygen availability, including VEGF and erythropoietin, commonly via changes that decrease HIF's degradation. 12 Interestingly, our findings suggest that HIV markedly induces HIF-2␣ but not HIF-1␣, indicating a hypoxia-independent pathway.
To identify which HIV-1-encoded gene was responsible for inducing expression of HIF-2␣ and VEGF, the genes for vpr, tat, and nef were introduced individually into conditionally immortalized podocytes. We found that only the nef gene was responsible for HIV-induced HIF-2␣ and VEGF expression in podocytes (Supplemental Figure 2) . Because we have shown previously that Nef activates the Src/Stat3 pathway in podocytes 13 and the Src/Stat3 pathway has been shown to mediate HIF-2␣ expression in other cell lines, 14 we investigated whether Src/Stat3 mediates Nef-induced HIF-2␣ expression in podocytes. We found that both pp2 (a Src kinase inhibitor) as well as a dominant negative mutant for Stat3 inhibited Nef-induced HIF-2␣ expression, suggesting that the Src/Stat3 pathway indeed mediates the Nef-induced increase in HIF-2␣ expression in podocytes (Supplemental Figure  2E) .
In vitro HIV-1-infected podocytes and podocytes from HIV-1-transgenic mice exhibit podocyte proliferation and loss of differentiation markers. 9, 15, 16 In vitro studies support a clear role for Nef in podocyte proliferation and de-differentiation 9 ; therefore, we determined whether VEGF mediates HIV/Nef-induced podocyte proliferation. We found that treatment with exogenous VEGF significantly increased podocyte number ( Figure 3A) . VEGF administration did not increase podocyte apoptosis or necrosis (data not shown). Levels of mRNA of the podocyte-specific marker synaptopodin were significantly decreased in VEGFstimulated podocytes ( Figure 3B ). VEGF also induced p44/42 mitogenactivated protein kinase (MAPK) phosphorylation ( Figure 3C ). Treatment of HIV-infected cells with recombinant sVEGFR1, which traps endogenous VEGF and inhibits its binding with cell surface receptors, significantly reduced podocyte proliferation induced by HIV ( Figure 3D ). These data suggest that VEGF mediates the effects of HIV-1 infection on podocyte proliferation and de-differentiation. Consistent with our studies, Ding et al. 17 showed that podocyte-specific deletion of the Von Hippel-Lindau gene (Vhlh) leads to stabilization of HIF-␣ subunits, causing podocyte proliferation and the development of the clinical features of rapidly progressive glomerulonephritis.
We also examined whether HIV infection regulates VEGF receptor expression in podocytes. We found that both protein and RNA expression of Flt1, Nrp-1, and VEGFR2 was increased and expression of Semaphorin 3A (Sema 3A) was downregulated in HIV-infected podocytes ( Figure 4A through C). VEGFR2 expression was also increased in podocytes from Tg26 mice ( Figure 4A ) and in HIVAN kidneys ( Figure 4D ). Human podocytes have been shown to express VEGFR1, VEGFR3, Nrp-1, and Nrp-2, and recent evidence suggests that VEGFR2 may be inducible in differentiated murine podocytes. 7, 18 Our data suggest that HIV may induce VEGFR2 expression in both human and murine podocytes.
Next, we determined whether VEGFR2 mediates the effects of HIV-1 on podocytes using both in vitro HIVinfected podocytes and podocytes isolated from Tg26 mice. We found that treatment with neutralizing antibodies against VEGFR2 caused less proliferation and increased synaptopodin expression both in HIV-infected and Tg26 podocytes when compared with podocytes treated with anti-flag antibody (Supplemental Figure 3) or rat IgG 2a (same IgG class of anti-VEGFR2 antibody; data not shown). These data support a role for VEGFR2 in HIV-induced podocyte proliferation and de-differentiation.
The precise role of VEGFR2 and Nrp-1 in podocyte biology and pathology remains unclear. Recent studies show that tyrosine kinase inhibitors that block the actions of the VEGF receptors can decrease podocyte proliferation. 7 Although Nrp-1 had previously been considered a nonsignaling VEGF co-receptor, VEGF has been shown to signal in an autocrine manner through Nrp-1 in the absence of Flk1 in breast carcinoma cells that are tyrosine kinase receptor negative. 19 HIV also induces upregulation of both VEGFR2 and its co-receptor Nrp-1, which may facilitate and enhance VEGF 165 's interaction with VEGFR2. 20 Interestingly, HIV infection also reduces podocyte expression of Sema 3A, which exerts its effects through its receptors Nrp-1 and plexinA. 21 Sema 3A has been recently shown to regulate expression and interactions among several slit-diaphragm proteins. 22 Our study demonstrates that NefSrc/Stat3-HIF-VEGF is a novel pathway for podocyte proliferation and dedifferentiation in HIVAN. In vivo, podocyte-specific expression of Nef in transgenic mice induces an abnormal podocyte phenotype characterized by increased Ki67, loss of synaptopodin, and increased phospho-Stat3. 15 These mice, however, do not have significant glomerulosclerosis (GS) or podocyte proliferation. One possible explanation is that these transgenic mice are on the C57/b6 background, which is known to be resistant to GS. 23 In contrast, recent studies have shown that podocyte-specific expression of Nef in transgenic mice on the FVB/N genetic background develop significant GS. 24 In these mice, podocytes exhibit a loss of differentiation markers in the absence of proliferation. Thus, the exact combination of factors that lead to podocyte proliferation in vivo remains unclear. 
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Our study also suggests the presence of a unique autocrine loop for VEGF in podocytes. Autocrine loops have been previously described in both endothelial and hematopoietic stem cells 25, 26 ; however, in both of these systems, treatment with VEGFR antagonists that act extracellularly fail to reverse the effects of VEGF, whereas those that are able to penetrate the intracellular compartment mimic the deletion of VEGF. 25, 26 In addition, exogenous treatment with VEGF is unable to compensate for the loss of endogenous VEGF in endothelial cells in which VEGF has been specifically deleted, suggesting the presence of an internal VEGF-dependent autocrine loop. 25 In contrast, we found that treatment with either soluble VEGFR or VEGFR2 neutralizing antibodies can reverse the podocyte proliferation and de-differentiation induced by HIV infection. Thus, it seems that the VEGF autocrine loop functions differently in podocytes.
In conclusion, our data show that HIV infection stimulates VEGF production in podocytes through the NefSrc/Stat3-HIF-2␣ pathway. Excess of VEGF production, along with upregulation of its receptors (VEGFR2 and Nrp-1) and downregulation of its protective ligand (Sema 3A), contributes to podocyte proliferation and loss of synaptopodin in HIVAN. Our data provide new insight into the underlying molecular mechanisms of podocyte disease of HIVAN. Future studies will determine whether administration of anti-VEGFR2 drugs could have beneficial effects in Tg26 mice, an animal model of HIVAN.
CONCISE METHODS

Immunohistochemistry and Immunofluorescence
Human biopsy specimens from patients with HIVAN and minimal-change disease were obtained courtesy of Dr. Vivette d'Agati (Columbia University) from routine biopsies performed after institutional review board approval. Paraffin-embedded and paraformaldehydefixed kidneys were obtained from Tg26 mice and their littermates. Five specimens from each group were tested with each antibody after they were dewaxed and rehydrated. Antigen retrieval was performed on Tg26 and littermate specimens after deparaffinizing and rehydrating the sections. The slides were immersed in citrate buffer (10 mM citric acid and 0.05% Tween 20 [pH 6.0]), heated to boiling point for 5 min, cooled to room temperature for 20 min, washed in PBS two times, and then followed by standard staining protocol. All specimens were incubated with primary antibody (anti-VEGF [ 
Conditionally Immortalized Murine Podocytes with HIV-1-Expressing or Control Vector
Conditionally immortalized murine podocytes were isolated as described previously. 27 Production of HIV-1 constructs has been described previously. 9 The podocytes used in these experiments are from an established line of pNL4-3:d1443 and pHR-CMV-IRES2-GFP-⌬B-infected podocytes. In all experiments, cells were grown at 37°C on type 1 collagen-coated dishes for 10 d to inactivate temperature-sensitive T antigen and allow for differentiation.
Northern Blot Analysis
Total RNA was extracted using Trizol (Life Technologies BRL, Grand Island, NY). VEGF, Sema 3A, and glyceraldehyde-3-phosphate dehydrogenase probes were generated by reverse transcriptase-PCR from RNA isolated from normal mouse glomeruli. The cDNA probes were radio- labeled with [ 32 P-␣]dCTP and hybridized with Hybrisol (Intergen, Purchase, NY).
Western Blot pNL4-3:d1443 and pHR-CMV-IRES2-GFP-⌬B-infected podocytes were lysed and subjected to Western blot analysis using the following antibodies: Neuropilin-1 (Abcam, Cambridge, MA), Flk1 (Santa Cruz Biotechnology), VEGFR2 (R&D Systems), Sema 3A (Abcam), and ␤-actin (Sigma-Aldrich). pNL4-3:d1443 and pHR-CMV-IRES2-GFP-⌬B podocytes were grown to confluence and stimulated with Mg132 (10 M; Calbiochem, La Jolla, CA) or dimethyl-sulfoxide (Sigma-Aldrich) at a concentration of 1:1000 overnight. Cell lysates and nuclear extracts were subjected to Western Blot analysis with anti-VEGF antibody (R&D Systems) and HIF-1␣ and HIF-2␣ antibodies (Novus Biologicals).
HIV-1 Constructs
The production of HIV-1 constructs has been described previously. 28 The vpr, tat, and nef constructs as well as a control green fluorescence protein-containing construct and a Stat3 dominant negative mutant (a gift from Dr. C.M. Horvath, The Rockefeller University, New York, NY) were individually introduced into wild-type conditionally immortalized podocytes maintained at 33°C via nucleofection (Amaxa Biosystems, Cologne, Germany), and the cells were transferred to 37°C for 3 d. 29 The transfection efficiency was evaluated by fluorescence microscopy confirming 70 to 80% efficiency.
Real-Time PCR
Real-time PCR was performed with a Roche LightCycler using a QuantiTect One Step RTPCR SYBR green kit (Qiagen, Valencia, CA) using validated primer sets for VEGF, endothelial PAS domain protein, and VEGFR2/kinase insert domain receptor (Qiagen). Meltingcurve analysis was performed to check for a single amplicon and verified by size using gel electrophoresis. Specific primers for synaptopodin (5Ј-GCC AGG GAC CAG CCA GAT A-3Ј and 3Ј-AGG AGC CCA GGC CTT CTC T-5Ј) and tubulin (5Ј-TGC CTT TGT GCA CTG GTA TG-3Ј and 3Ј-CTG GAG CAG TTT GAC GAC AC-5Ј) were designed (MWG-Biotech, High Point, NC). LightCycler analysis software was used for determining crossing points using the second derivative method. Data were analyzed by the 2 Ϫ⌬⌬ C T method and presented as fold increase normalized to the housekeeping gene tubulin. 30 
Cell Proliferation and Determination of Cell Signaling Activation and Differentiation
Conditionally immortalized podocytes were split and plated into 24-well collagen-coated plates at a density of 20,000 cells/well after differentiation. The cells were serum-starved overnight and exposed to medium with or without recombinant human VEGF 165 (R&D Systems) in concentrations of 0.1, 0.5, 1, or 5 nm. HIV-infected podocytes and their control cells were also exposed to recombinant sVEGFR1 (R&D Systems; 100 ng/ ml) daily for 3 d to block the effects of VEGF. Cells were trypsinized and counted on days 2 and 5. RNA was also isolated from samples and used for realtime PCR using a synaptopodin-specific primer.
Differentiated podocytes were stimulated for 0, 10, 20, 30, and 60 min with 1 nm of VEGF. Cell lysates were analyzed using Western blot analysis using antiphospho-MAPK1 and 2 and anti-MAPK1 and 2 (Cell Signaling Laboratory, Danvers, MA).
Determination of Podocyte Apoptosis/Necrosis
Differentiated podocytes were exposed to medium with or without VEGF in concentrations ranging from 0.1 to 10 nm, and apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling staining (Promega, Madison, WI). Apoptotic cells with nuclei staining dark brown were counted by light microscopy by two independent investigators. Apoptosis was expressed as the ratio of apoptotic cells to the total number of cells in the field of view. FACS was used to quantify apoptotic and necrotic podocytes after annexin V-FITC and propidium iodide labeling (BD Bioscience, San Jose, CA).
VEGFR2 Inhibition
Transgenic podocytes and in vitro HIV-1-infected podocytes were differentiated at 37°C for 7 d and then treated with either neutralizing antibody against VEGFR2/ Flk1 (1 g/ml; cat. no. MAB4431, rat IgG 2a class; R&D Systems) or an equivalent amount of a nonrelevant antibody (antiflag mAb of mouse IgG 1 ; cat. no. F3165; Sigma) or a rat IgG 2a isotype control.
The transgenic and HIV-infected podocytes were also split and plated into 24-well dishes at a density of 20,000 cells/ well and exposed to medium with anti-VEGFR2/Flk1 (1 g/ml) or anti-flag antibody. Cells were trypsinized and counted on day 3.
Statistical Analysis
All experiments were performed at least three times. In cell proliferation and realtime PCR results, data are expressed as means Ϯ SEM. Statistically significant differences between the means were determined by unpaired t test where appropriate. Significance was defined as P Յ 0.05.
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